| Literature DB >> 26120513 |
Margitta Worm1, Uta Jappe2, Jörg Kleine-Tebbe3, Christiane Schäfer4, Imke Reese5, Joachim Saloga6, Regina Treudler7, Torsten Zuberbier1, Anja Waßmann8, Thomas Fuchs9, Sabine Dölle1, Martin Raithel10, Barbara Ballmer-Weber11, Bodo Niggemann12, Thomas Werfel13.
Abstract
A large proportion of immunoglobulin E (IgE)-mediated food allergies in older children, adolescents and adults are caused by cross-reactive allergenic structures. Primary sensitization is most commonly to inhalant allergens (e.g. Bet v 1, the major birch pollen allergen). IgE can be activated by various cross-reactive allergens and lead to a variety of clinical manifestations. In general, local and mild - in rare cases also severe and systemic - reactions occur directly after consumption of the food containing the cross-reactive allergen (e. g. plant-derived foods containing proteins of the Bet v 1 family). In clinical practice, sensitization to the primary responsible inhalant and/or food allergen can be detected by skin prick tests and/or in vitro detection of specific IgE. Component-based diagnostic methods can support clinical diagnosis. For individual allergens, these methods may be helpful to estimate the risk of systemic reactions. Confirmation of sensitization by oral provocation testing is important particulary in the case of unclear case history. New, as yet unrecognized allergens can also cause cross-reactions. The therapeutic potential of specific immunotherapy (SIT) with inhalant allergens and their effect on pollen-associated food allergies is currently unclear: results vary and placebo-controlled trials will be necessary in the future. Pollen allergies are very common. Altogether allergic sensitization to pollen and cross-reactive food allergens are very common in our latitudes. The actual relevance has to be assessed on an individual basis using the clinical information. Cite this as Worm M, Jappe U, Kleine-Tebbe J, Schäfer C, Reese I, Saloga J, Treudler R, Zuberbier T, Wassmann A, Fuchs T, Dölle S, Raithel M, Ballmer-Weber B, Niggemann B, Werfel T. Food allergies resulting from immunological cross-reactivity with inhalant allergens. Allergo J Int 2014; 23: 1-16 DOI 10.1007/s40629-014-0004-6.Entities:
Year: 2014 PMID: 26120513 PMCID: PMC4479449 DOI: 10.1007/s40629-014-0004-6
Source DB: PubMed Journal: Allergo J Int ISSN: 2197-0378
|
|
|
|---|---|
|
| |
| Tree pollen | Apple, hazelnut, carrot, cherry, green kiwi, nectarine, peach, apricot, plum, celery, soya, fig |
|
| |
| Mugwort pollen | Spices, carrot, mango, celery, sunfl ower seeds |
| Natural latex | Avocado, banana, kiwi, tomato, chestnuts, peach, mango, papaya, acerola cherry, celery |
|
| |
|
| (Dried) figs, kiwi, banana, papaya [ |
| Bird feathers | Egg, poultry, offal |
| House dust mites | Crustaceans and mollusks |
| Animal epithelia | Meat |
|
| |
| Ragweed (ambrosia) pollen | Melon, zucchini, cucumber, banana |
| Grass and cereal pollen* | Flour, bran, tomato, legumes |
*Considering the high frequency with which grass and cereal allergies occur, cross-reactions with food allergens are very rare
|
|
|
|
|---|---|---|
| Clinically relevant allergy to pollen and local reactions after intake of the corresponding cross-reactive food | Depending on case history, confi rmation of sensitization to pollen by skin prick or specifi c serum IgE testing | Recommendation to avoid eating the food or opt for alternative methods of preparation as soon as local reactions develop; inform patient of factors with a potential infl uence, particularly during the pollen season |
| Clinically relevant allergy to inhalant allergens and systemic allergic reactions after intake of the corresponding cross-reactive food* | Depending on the case history, confi rmation of sensitization to pollen and food by skin prick and/or in vitro IgE testing | Recommendation to avoid eating the food; inform patient of factors with a potential infl uence, particularly during the pollen season |
| Unclear symptomatic response to inhalant allergens and a systemic allergic reaction after intake of a cross- reactive food* | Depending on case history and the nutrition and symptoms log, skin prick and/or in vitro IgE testing with inhalant allergens and foods; followed by oral provocation testing under clinical observation | Recommendation to avoid eating the food if there was a positive provocation reaction; inform patient of factors with a potential influence, particularly during the pollen season |
*e. g. birch — carrot, mugwort — celery, house dust mites — shrimps, latex — banana
|
|
|
|
|
|
|---|---|---|---|---|
| Peach | Prup 1 | Bet v 1 homolog | oral | Pru p 1a,b
|
| Pru p 4 | Profilin | usually oral | Pru p 4a,b
| |
| Pru p 3 | Lipid transfer protein | oral and/or systemic | Pru p 3a,b,c | |
| Melon | Cuc m 1 | Cucumisin | oral and/or systemic | N/A |
| Cuc m 2 | Profilin | oral | Bet v 2a,b,c,d,e | |
| Cuc m 3 | PR-1 | oral and/or systemic | not available | |
| Peanut | Ara h 1 | Cupin superfamily: vicilin | systemic | Ara h 1a,b |
| Ara h 2 | Prolamin: 2S albumin | systemic | Ara h 2a,b,d | |
| Ara h 3 | Cupin superfamily: legumin | systemic | Ara h 3a,b | |
| Ara h 5 | Profilin | usually oral | Bet v 2 | |
| Ara h 8 | Bet v 1 homolog | oral | Ara h 8a,b
| |
| Ara h 9 | Prolamin superfamily Lipid transfer protein | oral and/or systemic | Ara h 9a,b, Pru p 3a,b,c | |
| Ara h 10 | Oleosin | systemic | nicht verfügbar | |
| Hazelnut | Cor a 1 | Bet-v-1 homolog | oral and/or systemic | Cor a 1a,b,d
|
| Cor a 8 | Prolamin superfamily lipid transfer protein | systemic | Cor a 8a,b | |
| Kiwi | Act d 8 | Bet v 1 homolog | oral and/or systemic (typically mild reactions) | Act d 8a,b, Bet v 1a,b,c,d,e |
| Celery | Api g 1.01 | Bet v 1 homolog | oral and/or systemic (typically mild reactions) | Api g 1a,b
|
| Soy | Gly m 4 | Bet v 1 homolog | oral or systemic (sometimes severe) | Gly m 4a,b, Bet v 1a,b,c,d,e |
| Shrimps | Pen a 1 | Tropomyosin | systemic | Pen a/m 1a,b,c,e
|
aImmunoCAP® singleplex determinations; bImmunoCAP® ISAC microarray (Thermo Fisher); cImmulite® (Siemens-Healthcare); dAllerg-O-Liq (Dr. Fooke Laboratories); eAllergozyme® (Omega)
|
|
|
|---|---|
| High proportion of cross-reactive antibodies | (Orally) consumed quantity |
| Adequate binding strength (avidity) of the cross-reactive antibody | Proportion of the cross-reactive allergen in the food |
| Cross-reactive antibody-mediated recognition of multiple epitopes | Similarity, number and stability of cross-reactive epitopes |
IgE, immunoglobulin E
|
|
| Sensitizations to various inhalant allergens are responsible for a broad spectrum of sensitizations to foods |
| Demonstration of a sensitization by skin or in vitro testing does not constitute proof of clinical relevance. Positive case history is of greater importance than a confirmed sensitization |
| General dietary recommendations should not be made on the basis of a proven crossreactivity between inhalant and food allergens |
| Potential augmentation factors should be considered |
| For some food allergies, the prick-to-prick test using fresh material is better than prick testing with commercially available food extracts for determining sensitizations |
| In vitro testing of individual allergens (component-based diagnosis) can be helpful for individual determination of sensitization to plants. Testing of individual allergens can also be helpful for assessing the individual risk of systemic reaction profile |
| In the case of unclear case history, it may be useful to implement and analyze a nutrition and symptom diary |
| Avoidence or re-exposure and/or oral provocation testing with the presumed reactive food is necessary before performance of a therapeutic elimination diet |
| Specific immunotherapy with cross-reactive inhalant allergens for treatment of a food allergy alone is not recommended; indications should be the respiratory symptoms |
|
|
|
|---|---|
| Preparation | Documentation of initial condition |
|
| |
| Retain increasing quantities (e.g. 5, 10, 20, 40 ml) of allergen drink in mouth for 1 min; spit out; wait for 15 min | Oropharyngeal symptoms (irritation and swelling of mouth and throat) or clinical allergy symptoms |
| Retain increasing quantities (e.g. 5, 10, 20, 40 ml) of placebo drink in mouth for 1 min; spit out; wait for 15 min | No symptoms |
| Interpretation: result positive if localized oropharyngeal symptoms are observed three times or upon real positive symptoms following allergen provocation with a negative placebo reaction | |
|
| |
| Swallow increasing quantities (e.g. 10, 20, 40, 80 ml) of allergen drink; increase dose every 15 min | Oropharyngeal symptoms, rhinoconjunctivitis, urticaria, angioedema, vomiting, diarrhea, dyspnea, reduced blood pressure |
| Swallow increasing quantities (e.g. 10, 20, 40, 80 ml) of placebo drink; increase dose every 15 min | No symptoms |
| Interpretation: result positive if symptoms are observed upon allergen provocation three times and the placebo reaction is negative | The order of the verum and placebo administrations set in a blinded manner. Allergen dosage and the number of administrations depend on the patient’s case history. Where case history reveals that symptoms do not develop in the mouth or throat, step 1 can be omitted |
| Individual pollen sensitization profile | |
| Cumulative eff ect of high pollen count | |
| Physical exercise | |
| Bronchial asthma (severity or medication) | |
| Simultaneous gastrointestinal disease | |
| Meal size and composition (matrix effect) | |
| Quantity of allergen and cumulative eff ect of cross-reactive food consumption | |
| Simultaneous intake of: | - Medication with an influence on allergen stability (e.g. proton pump inhibitors) |
NSAID, nonsteroidal anti-inflammatory drugs
|
|
|
|
|
|
|---|---|---|---|---|
| Mal d 1 | Apple ( | Rosaceae | Vanek-Krebitz et al. 1995 [ | |
| Cor a 1.04 | Hazelnut ( | Corylaceae | Breiteneder et al. 1993 [ | |
| Api g 1 | Celery ( | Apiaceae | Breiteneder et al. 1995 [ | |
| Dau c 1 | Carrot ( | Apiaceae | Hoff mann-Sommergruber et al. 1999 [ | |
| Bet v 1 (PR-10) | Pru av 1 | Cherry ( | Rosaceae | Scheurer et al. 1997 [ |
| Pyr c 1 | Pear ( | Rosaceae | Karamloo et al. 2001 [ | |
| Act d 8 | Green kiwi ( | Actinidiaceae | Oberhuber et al. 2008 [ | |
| Act c 8 | Yellow kiwi ( | Actinidiaceae | Oberhuber et al. 2008 [ | |
| Gly m 4 | Soy bean ( | Fabaceae | Kleine-Tebbe et al. 2002 [ | |
| Ara h 8 | Peanut ( | Fabaceae | Mittag et al. 2004 [ | |
| Vig r 1 | Mung bean ( | Fabaceae | Mittag et al. 2005 [ |
PR-10, pathogenesis-related protein family 10
|
|
|
|
|---|---|---|
| Celery-birch-mugwort-spice syndrome* | Celery and/or other vegetables and spices of the umbelliferous plant family (e.g. carrots, parsley; caraway, fennel, coriander and anise seeds) | Wüthrich and Dietschi 1985 [ |
| Celery-birch-spice syndrome | Plants of the Umbelliferae, Solanaceae (paprika), Piperaceae (pepper), Sumach (mango) and Liliaceae (garlic, onion) families | Egger et al. 2006 [ |
| Mugwort-mustard allergy syndrome | Mustard, cruciferous vegetables other than mustard (e.g. broccoli, cabbage and caulifl ower), nuts, pulses, fruits of Rosaceae, cereals | Figueroa et al. 2005 [ |
| Mugwort-peach syndrome | Peach (allergy triggered by LTP Art v 3 and Pru p 3) | Pastorello et al. 2002 [ |
LTP, Lipid transfer protein
*Frequently observed in birch pollen allergy patients; rarer among mugwort allergy patients
|
|
|
|
|---|---|---|
| Major allergens (e. g. medical personnel) | Hev b 5, Hev b 6.01 and Hev b 6.02 | Mari et al. 2007 [ |
| Major allergens (patients undergoing frequent surgery, e. g. spina bifi da) | Hev b 1 and Hev b 3 | Raulf-Heimsoth et al. 2007 [ |
| Cross-reactive allergen in latex-fruit syndrome | Hev b 2, Hev b 6.01, Hev b 6.02, Hev b 6.03, Hev b 7, Hev b 8 and Hev b 11, Hev b 12 | Wagner and Breiteneder 2005 [ |
| No or low clinical relevance | Cross-reactive carbohydrate determinant (CCD) | Raulf-Heimsoth et al. 2007 [ |
LTP, Lipid transfer protein
*Frequently observed in birch pollen allergy patients; rarer among mugwort allergy patients